Significance of Drug Dose, Timing and Radiotherapy in Adjuvant Therapy of Breast Cancer
In the past decade, many adjuvant chemotherapy trials in operable breast cancer have been conducted. The results of these trials have answered a number of questions, but have also raised new issues. Among other issues, results have suggested that relapse-free survival was dependent on the dose of cytotoxic drugs and the timing of initiation of chemotherapy [1, 2]. Routine postoperative irradiation was shown to have a detrimental effect on the efficacy of adjuvant chemotherapy [2, 3]. At M.D. Anderson Hospital, since 1974, a combination of fluorouracil, doxorubicin (adriamycin), and cyclophosphamide (FAC) has been utilized following regional therapy in patients with operable breast cancer. In this paper the dose of cytotoxic drugs, timing of initiation of chemotherapy, and the role of routine postoperative irradiation are evaluated.
KeywordsBreast Cancer Adjuvant Chemotherapy Operable Breast Cancer Granulocyte Count Pretreatment Characteristic
Unable to display preview. Download preview PDF.
- 4.Buzdar A, Smith T, Blumenschein G, Hortobagyi G, Hersh E, Gehan E (1981) Adjuvant chemotherapy with fluorouracil, doxorubicin and cyclophosphamide (FAC) for stage II or III breast cancer: 5-year results. In: Salmon SE, Jones SE (eds) Adjuvant therapy of cancer III. Grune and Stratton, New York, pp 419–426Google Scholar
- 5.Buzdar A. Blumenschein G, Smith T et al. (1984) Adjuvant chemotherapy with fluorouracil, doxorubicin, and cylophosphamide, with our without Bacillus Calmette-Guerin and with or without irradiation in operable breast cancer. A prospective randomized trial. Cancer 53: 384–389Google Scholar
- 10.Buzdar A, Smith T, Blumenschein G et al. (1984) Adjuvant therapy for stage II or III breast cancer M.D. Anderson Hospital experience. In: Blumenschein GR, Montague E (eds) Current controversy in breast cancer. Proceedings of the 26th annual clinical conference, New York, pp 171–184Google Scholar